Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 17/20 | 0.62 |
| ▸ | PDCD1 | Q15116 | 14/20 | 0.62 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19549760 | 0.80 | CD274 (0.71) | CD274PDCD1TLR9TLR8TLR7 | |
| SCHEMBL19549669 | 0.79 | CD274 (0.77) | CD274PDCD1TLR9TLR8TLR7 | |
| SCHEMBL3669729 | 0.78 | PDCD1 (0.52) | CD274PDCD1TLR9TLR8TLR7 | |
| SCHEMBL30504422 | 0.77 | CD274 (0.68) | CD274PDCD1TLR9TLR8TLR7 | |
| SCHEMBL19549722 | 0.77 | PDCD1 (0.82) | CD274PDCD1CYP3A4 | |
| SCHEMBL19549793 | 0.77 | CD274 (1.00) | CD274PDCD1TLR9TLR8TLR7 | |
| SCHEMBL20324274 | 0.76 | PDCD1 (0.66) | CD274PDCD1TLR9TLR8TLR7 | |
| SCHEMBL19549699 | 0.75 | PDCD1 (1.00) | CD274PDCD1TLR9TLR8TLR7 | |
| SCHEMBL30504452 | 0.73 | CD274 (0.63) | CD274PDCD1TLR9TLR8TLR7 | |
| SCHEMBL19549737 | 0.73 | PDCD1 (1.00) | CD274PDCD1TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11608337-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | claimed |
| EP-3452476-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-12-15 | — | — | EP | claimed |
| EP-3452476-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | Incyte Holdings Corporation (US) | 2019-03-13 | — | — | EP | claimed |
| US-20190071439-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-03-07 | — | — | US | claimed |
| US-20170320875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-09 | — | — | US | claimed |
| WO-2017192961-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2017-11-09 | — | — | WO | claimed |
| US-20230192689-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-20230192689-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-20230192689-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2023-06-22 | — | — | US | disclosed |
| US-11608337-B2 | Heterocyclic compounds as immunomodulators | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | disclosed |
| EP-3452476-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-12-15 | — | — | EP | disclosed |
| EP-3452476-B1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-12-15 | — | — | EP | disclosed |
| US-20210017175-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2021-01-21 | — | — | US | disclosed |
| US-20200172541-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2020-06-04 | — | — | US | disclosed |
| US-20190071439-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-03-07 | — | — | US | disclosed |
| US-20190071439-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2019-03-07 | — | — | US | disclosed |
| US-20170320875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-09 | — | — | US | disclosed |
| US-20170320875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-09 | — | — | US | disclosed |
| US-20170320875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION | 2017-11-09 | — | — | US | disclosed |
| WO-2017192961-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | INCYTE CORPORATION (US) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192689-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CD274 88/4885PDCD1 157/4885TLR9 112/4885 |
| US-20190071439-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CD274 88/4885PDCD1 157/4885TLR9 112/4885 |
| US-20170320875-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CD274 88/4885PDCD1 157/4885TLR9 112/4885 |
| US-20200172541-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CD274 88/4885PDCD1 157/4885TLR9 112/4885 |
| US-11608337-B2 | Heterocyclic compounds as immunomodulators | CD74, IL2, ICOS | CD274 88/4885PDCD1 157/4885TLR9 112/4885 |
| US-20210017175-A1 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS | CD74, IL2, ICOS | CD274 88/4885PDCD1 157/4885TLR9 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.